Completion of the final patient's final visit during the double-blind treatment period of the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS)
MediciNova, Inc. (filing company)
MN-166 (ibudilast); COMBAT-ALS clinical trial in ALS
The company stated that completion was achieved with the cooperation of the patients who participated in the trial, principal investigators, sub-investigators, clinical trial coordinators, medical staff at each participating medical institution and other parties involved.
No impact (on the company's consolidated results for the fiscal year ending December 2026)
No impact on the Company's consolidated results forecast for the fiscal year ending December 2026
Related procedures
Clinical trial progress report
The company plans to proceed with database lock and data analysis for the double-blind portion and announce topline data at the end of 2026.
Topline data are scheduled to be announced at the end of 2026.
| Item | Details |
|---|---|
| Event name | Completion of the final patient's final visit during the double-blind treatment period of the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) |
| Date of occurrence | 24 September 2026 |
| Date recognized / date notice received | 24 September 2026 |
| Subject Entity | MediciNova, Inc. (filing company) |
| Target Locations / Products | MN-166 (ibudilast); COMBAT-ALS clinical trial in ALS |
| Cause | The company stated that completion was achieved with the cooperation of the patients who participated in the trial, principal investigators, sub-investigators, clinical trial coordinators, medical staff at each participating medical institution and other parties involved. |
| Amount of Impact on Business Performance | No impact (on the company's consolidated results for the fiscal year ending December 2026) |
| Impact on Earnings Forecast | No impact on the Company's consolidated results forecast for the fiscal year ending December 2026 |
| Type of litigation or proceeding | Clinical trial progress report |
| Outlook | The company plans to proceed with database lock and data analysis for the double-blind portion and announce topline data at the end of 2026. |
| Planned follow-up disclosure | Topline data are scheduled to be announced at the end of 2026. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company stated that the final patient's final visit was completed with the cooperation of the patients who participated in the trial, medical staff and other parties involved.